Purchase Order 75N92B21P00003
Award Date 10/29/20
Potential Completion Date 10/29/20
Potential Value $23K
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
East Yaphank, NY 11967, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- <p>The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded a purchase order to Adaptive Biotechnologies Corporation for $29,900.00 on September 12, 2019, for ImmunoSEQ HSTCRB V4 assay services. Performance of work is located in Bethesda, Maryland, with a completion date of February 28, 2020. The purchase order was issued without a set-aside designation under a pre-solicitation opportunity posted July 24, 2019.</p>
- <p>The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded a purchase order to Fisher Scientific Company L.L.C. valued at $13,126.61 on August 3, 2020 for an instrument to obtain thin-layer cell preparation on a glass slide for immunocytochemistry in diagnosis, prognosis, and therapeutic applications. Performance is at Hanover Park, Illinois. The order is firm fixed price with an ultimate completion date of January 12, 2021.</p>
- <p>The National Cancer Institute awarded a purchase order to Creative Biolabs Inc. for recombinant antibody production on December 10, 2020, with a ceiling value of $19,800.00. The order is firm fixed-price with an ultimate completion date of January 7, 2021. Work is performed in East Yaphank, New York.</p>
- <p>The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded a purchase order to 10X Genomics, Inc. valued at $185,142 on September 28, 2020 for reagents compatible with the Chromium Controller single cell platform.</p> <p>Work is performed at Bethesda, Maryland. The order is firm fixed price with an ultimate completion date of October 30, 2020. No set-aside was used.</p>
- <p>The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded a purchase order to ProteinSimple for $37,250 on September 28, 2020, for acquisition of an automated immunoassay system. Place of performance is Bethesda, Maryland. The order carries a fixed-price award-fee structure with an ultimate completion date of November 30, 2020. No set-aside designation applied to this acquisition.</p>
- CD Biosciences Inc., doing business as Creative Biomart, Creative Biolabs, CD Genomics, and Profacgen Division, has been awarded a $15,000 firm fixed price purchase order by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to provide creative diagnostics glycoproteins and nucleoproteins. The contract has a period of performance from September 22, 2023 through December 29, 2023, with all work to be conducted by the prime contractor in East Yaphank, New...
- <p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for customized DNA and monoclonal antibody production, valued at $49,653.58, on August 6, 2020. Performance is located in Piscataway, New Jersey. The order is firm fixed price with an ultimate completion date of September 5, 2020.</p>
- <p>The National Institute of Arthritis and Musculoskeletal and Skin Diseases issued a delivery order to Illumina, Inc. on July 27, 2015, with a ceiling value of $89,483.32 and an ultimate completion date of August 15, 2016.</p> <p>Place of performance is Bethesda, Maryland. The order is priced on a firm fixed-price basis with no set-aside designation. The source does not identify the parent vehicle under which this delivery order was issued.</p>
- <p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. valued at $14,979.75 on August 29, 2024, for monoclonal antibodies and plasmids services. The order is firm fixed price with no small business set-aside. Performance occurs in Piscataway, New Jersey. The modification de-obligates excess funds, with ultimate completion scheduled for May 18, 2026.</p>
- <p>The National Institute of Arthritis and Musculoskeletal and Skin Diseases issued a $101,126.67 delivery order to Illumina, Inc. on January 25, 2017, with an ultimate completion date of January 24, 2018.</p> <p>Place of performance is Bethesda, MD 20892. The order is firm fixed price with no set-aside. The source does not identify the parent vehicle governing this delivery order or specify the equipment or services being procured.</p>